Brief: Cantargia Presents Preclinical Data Demonstrating Unique Treatment Effects Of Nadunolimab On Pancreatic Cancer Stromal Cells
13/09/2022 22:33
Sept 13 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA PRESENTS PRECLINICAL DATA DEMONSTRATING UNIQUE
TREATMENT EFFECTS OF NADUNOLIMAB ON PANCREATIC CANCER STROMAL
CELLS
* CANTARGIA - FINDINGS INDICATE IL1RAP BLOCKADE BY
NADUNOLIMAB HAS
AN INFLUENCE ON MICROENVIRONMENT OF PDAC TUMORS NOT ACHIEVED BY
IL-1Β BLOCKADE ONLY
* CANTARGIA - NEW RESULTS SHOW THAT NADUNOLIMAB REDUCES PDAC
TUMOR
GROWTH THROUGH A STRONG IMPACT ON CANCER-ASSOCIATED FIBROBLASTS
Source text for Eikon: ID:nWkr1y0LMm
Further company coverage: CANTA.ST
((reuters.briefs@thomsonreuters.com;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML